NewsBenzingaWave Life Sciences Plans For Two-Year Registrational Trial For WVE-006 To Treat Alpha-1 Antitrypsin Deficiency Wave Life Sciences Plans For Two-Year Registrational Trial For WVE-006 To Treat Alpha-1 Antitrypsin Deficiency Benzinga 2026.10.01 11:31 (GMT+0) Open on Benzinga Other news Roth Capital Reiterates Buy on Zeta Global Holdings, Raises Price Target to $55 Tesla Faces New Luxury EV Rival in France as Lucid Plans 16 Locations 'Mark Zuckerberg says Meta has reached AI ‘frontier’ and rejects calls for slowdown' - FT Interview Roth Capital Reiterates Buy on Standard Motor Products, Maintains $54 Price Target Why Is Oracle Stock Falling on Monday? HC Wainwright & Co. Maintains Buy on Mirum Pharmaceuticals, Raises Price Target to $200
